65399-03-3

Basic information

• Product Name: 5-METHYL-2,3-DIHYDRO-ISOINDOL-1-ONE
• Synonyms: 5-METHYL-2,3-DIHYDRO-ISOINDOL-1-ONE;5-METHYLISOINDOLIN-1-ONE;5-Methyl-1-oxo-isoindoline;1H-Isoindol-1-one,2,3-dihydro-5-Methyl-;5-Methyl-1-isoindolinone
• CAS NO: 65399-03-3
• Molecular Formula: C9H9NO
• Molecular Weight: 147.17
• Mol File: 65399-03-3.mol

Chemical Properties

• Appearance: /
• Density: 1.155±0.06 g/cm3 (20 ºC 760 Torr)
• CAS DataBase Reference: 5-METHYL-2,3-DIHYDRO-ISOINDOL-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHYL-2,3-DIHYDRO-ISOINDOL-1-ONE(65399-03-3)
• EPA Substance Registry System: 5-METHYL-2,3-DIHYDRO-ISOINDOL-1-ONE(65399-03-3)

Safety Data

• Hazardous Substances Data: 65399-03-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
5-METHYL-2,3-DIHYDRO-ISOINDOL-1-ONE is used as a key intermediate in the synthesis of pharmaceuticals for its potential to contribute to the development of new drugs. Its unique structure allows it to be a building block in the creation of various medicinal compounds.
Used in Agrochemical Synthesis:
In the agrochemical industry, 5-METHYL-2,3-DIHYDRO-ISOINDOL-1-ONE is utilized as a precursor in the production of agrochemicals, such as pesticides and herbicides, due to its ability to enhance the effectiveness of these products.
Used in Research and Development:
5-METHYL-2,3-DIHYDRO-ISOINDOL-1-ONE serves as a valuable compound in research and development settings, where it is used to explore new chemical reactions and investigate its potential applications in various fields.
Used in Organic Electronics:
Due to its electronic and optical properties, 5-METHYL-2,3-DIHYDRO-ISOINDOL-1-ONE has potential applications in the field of organic electronics. It may be employed in the development of organic light-emitting diodes (OLEDs), organic solar cells, and other electronic devices that require materials with specific electronic characteristics.

Upstream product

• 64-17-5 ethanol 
• 40314-06-5 5-methyl-1H-isoindole-1,3-(2H)-dione 
• 867350-27-4 N-(3-methylbenzyl)picolinamide 
• 1972-28-7 diethylazodicarboxylate 
• 201230-82-2 carbon monoxide 
• 100-81-2 3-methyl-benzenemethanamine 

Relevant articles and documents

Palladium-Catalyzed Direct C-H Carbonylation of Free Primary Benzylamines: A Synthesis of Benzolactams

A protocol for palladium-catalyzed C-H carbonylation of readily available free primary benzylamines using NH2 as the chelating group under an atmospheric pressure of CO has been achieved, providing a general, atom- and step-economic approach to

Traceless Directing Group Assisted Cobalt-Catalyzed C?H Carbonylation of Benzylamines

The first example of cobalt-catalyzed C(sp2)?H carbonylation of benzylamines using a traceless directing group is reported, which was successfully applied to the synthesis of N?unprotected iso-indolinones through direct C?H/N?H bonds activation. This protocol tolerates a variety of functional groups and provides a facile and efficient method for the formal synthesis of (+)-garenoxacin. (Figure presented.).

CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS

Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, are useful as kinase modulators, including Btk modulation.

N-heterocyclic inhibitors of TNF-α expression

N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-α expression utilizing compounds of the present invention are also disclosed.

N-heterocyclic inhibitors of TNF-alpha expression

N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-α expression utilizing compounds of the present invention are also disclosed.

N- heterocyclic inhibitors of TNF-alpha expression

N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-α expression utilizing compounds of the present invention are also disclosed.